Login / Signup

Comparative oncology reveals DNMT3B as a molecular vulnerability in undifferentiated pleomorphic sarcoma.

Ashley M FullerAnn DeVineIleana MurazziNicola J MasonKristy WeberT S Karin Eisinger-Mathason
Published in: Cellular oncology (Dordrecht) (2022)
DNMT3B represents a promising molecular susceptibility in UPS, but further development of DNMT3B-targeting strategies for these patients is required.
Keyphrases
  • dna methylation
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • palliative care
  • climate change
  • peritoneal dialysis
  • prognostic factors
  • cancer therapy
  • patient reported outcomes
  • drug delivery